Effect of Cariprazine on Anhedonia in Patients with Bipolar I Depression: Post Hoc Analysis of Three Randomized Placebo-Controlled Clinical Trials DOI Creative Commons
Roger S. McIntyre, Pierre‐Michel Llorca,

Lauren C. Aronin

et al.

Advances in Therapy, Journal Year: 2024, Volume and Issue: 42(1), P. 246 - 260

Published: Nov. 9, 2024

Anhedonic symptoms in bipolar I (BP-I) depression are associated with decreased quality of life and impaired functioning. We evaluated the effects cariprazine patients BP-I lower or higher levels anhedonia at baseline. Data were pooled from three clinical trials (NCT01396447, NCT02670538, NCT02670551) analyzing 1.5 3 mg/day adults depression. During post hoc analysis, stratified by baseline median Montgomery-Åsberg Depression Rating Scale (MADRS) factor score into a (score < median) ≥ subgroup. Outcomes included change to week 6 MADRS total score, latter also after adjusting for other depressive symptoms. Between-group differences compared using least-squares mean (LSMD) analyzed via mixed-effect model repeated measures. Median was 19, defining (placebo = 211; 200, 212) 249; 261, 250) subgroups. In subgroup, but not superior placebo reducing (LSMD [95% CI] − 2.61 [− 4.28, 0.93], P .0024) scores (− 1.70 2.77, 0.62], .0021) 6. both doses significantly greater reductions than (1.5 3.01 4.84, 1.19], .0012; 3.26 5.12, 1.40], .0006) 1.97 3.13, 0.81], .0009; 2.07 3.26, 0.89], .0006). Anti-anhedonic preserved symptoms, suggesting effect pseudospecific. Patients subgroup had therefore may have floor effect. Cariprazine demonstrated antidepressant specific anti-anhedonic regardless ClinicalTrials.gov identifiers, NCT02670551, NCT01396447. Anhedonia, lack interest pleasure, is common medication approved treatment However, its on unclear. To understand anhedonia, we combined data trials. mg per day) weeks against who before they started treatment. A 1383 study. There 623 760 anhedonia. more depressed overall those day better Our results suggest that reduces

Language: Английский

Exploring the Bidirectional Relationship Between Depression and Obesity DOI
Seon‐Cheol Park, Takahiro A. Kato, Yena Lee

et al.

Endocrinology and Metabolism Clinics of North America, Journal Year: 2025, Volume and Issue: 54(1), P. 193 - 206

Published: Feb. 5, 2025

Language: Английский

Citations

1
The association between Metabolic Score for Visceral Fat and depression in overweight or obese individuals: evidence from NHANES DOI Creative Commons
Heng Liu,

Huqiang Dong,

Yu Zhou

et al.

Frontiers in Endocrinology, Journal Year: 2024, Volume and Issue: 15

Published: Sept. 26, 2024

Background Depression is a common mental illness with high prevalence in overweight or obese individuals. Recent studies suggest that the Metabolic Score for Visceral Fat (METS-VF) novel metric assessing visceral fat levels, potentially linking metabolic disturbances to depression. This study explores association between METS-VF and depression severity U.S. adults. Methods Data were obtained from National Health Nutrition Examination Survey (NHANES) 2007-2018 dataset, including 9,415 participants. was measured using Patient Questionnaire-9 (PHQ-9). To assess depression, methodology included multivariate logistic regression, subgroup analyses, generalized additive model (GAM), smoothed curve fitting. also calculated BMI Non-Hispanic Asian population 2011-2018 incorporated this data as part of sensitivity analysis. Results Elevated levels participants significantly associated increased PHQ-9 scores an likelihood Notably, remained significant after adjustment multiple covariates. Smoothed curve-fitting plots showed no nonlinear scores. Subgroup analyses confirmed robustness these results across populations, particularly among people under age fifty. The study. Conclusion positively individuals, being pronounced 50 years age.

Language: Английский

Citations

6
Tobacco smoking and the risk of eating behaviors and depression among Palestinian female university students DOI Creative Commons
Basma Damiri,

Thabet Zidan,

Dalia Hamayel

et al.

Discover Mental Health, Journal Year: 2025, Volume and Issue: 5(1)

Published: March 10, 2025

Tobacco smoking and eating disorders are often connected to concerns about body image can be indicative of underlying mental health conditions, such as depression. In Palestinian society, females have a cultural belief that aid in weight loss. Societal pressure on may drive risky behaviors. However, few studies examined the link between disorder We researched prevalence tobacco among female university students its association with binge/purge behaviors A cross-sectional research study was carried out at An-Najah National University. Female [N = 642] completed anonymous surveys, sharing information other substance use habits, answering questions from Eating Attitude Test-26, Sick (EAT-26), Control, One, Fat, Food (SCOF) screening tests, Beck Depression Inventory. The reported high waterpipe (24.4%) students, which exceeded cigarette (4%). For SCOF scale, 36.3% scored ≥ 2 points, indicating screened positive for anorexia or bulimia nervosa; 40% struggled binge-eating behavior, while only 7.8% had sought treatment disorders. Additionally, 34.7% experienced adjusted binary logistic regression model risk factors has shown is significantly associated self-induced vomiting (aOR 6.075, p-value 0.027), history 3.438, 0.047), e-cigarettes 10.070, 0.001), 3.299, 0.022), energy drinks 5.163, 0.003), moderate depression 11.499, 0.010), mild 12.963, 0.003). revealed concerning results linked depression, behaviors, obesity, various weight-control methods. These findings highlight urgent need targeted interventions through awareness campaigns, culturally tailored education, implementation support provide accessible medical psychological assistance at-risk students.

Language: Английский

Citations

0
Treating obesity in patients with depression: a narrative review and treatment recommendation DOI
Pamela Kushner, Scott Kahan,

Roger S. McIntyre

et al.

Postgraduate Medicine, Journal Year: 2025, Volume and Issue: unknown

Published: March 19, 2025

The high morbidity of obesity and depression pose significant public health concerns, with the prevalence doubling in US between 1990 2022 patients frequently presenting both. Untreated can greatly impact patient well-being, as both are associated a number comorbidities including sleep apnea, type 2 diabetes mellitus, metabolic syndrome, dysfunction-associated steatotic liver disease, cardiovascular disease. This narrative review aims to provide comprehensive current overview overlapping etiologies well available treatment options that may be recommended by primary care professionals treat these concomitant depression. With considerable overlap population depression, neurobiological, hormonal, inflammatory pathways underlying diseases, should consider screening for Holistic options, lifestyle behavioral modifications, pharmacotherapy bariatric surgery critical manage conditions simultaneously. Therefore, due neurobiological mechanisms responsible incidence progression holistic plan strategies efficacy any additional improve clinical approach

Language: Английский

Citations

0
A systematic review on the efficacy of GLP-1 receptor agonists in mitigating psychotropic drug-related weight gain DOI Open Access

Trisha Menon,

Serene M. L. Lee, Xiaowen Gong

et al.

CNS Spectrums, Journal Year: 2024, Volume and Issue: 29(5), P. 347 - 353

Published: Oct. 1, 2024

Abstract Objective Many psychotropic drugs are highly associated with related weight gain. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) established anti-obesity and glucose-lowering agents. Preliminary evidence also indicates they fit for purpose in mitigating drug-related gain (PDWG). This systematic review aims to synthesize the extant from randomized controlled trials (RCTs) on effects of GLP-1RAs change persons experiencing PDWG. Methods Online databases (ie, PubMed, OVID Medline, Google Scholar) were searched identify relevant studies inception January 1, 2024. Articles screened by title, abstract, full-text three independent reviewers against inclusion exclusion criteria. Results We identified six participants aged ≥18 (n=374) that eligible our review. Most reported a significant clinically meaningful effect anthropometrics and/or metabolics. All RCTs replicated finding modest or greater GLP-1RAs; most studied agents liraglutide exenatide. There was insufficient literature conduct meta-analysis. Conclusion Evidence suggests effective prescribed psychiatric medication. It is hypothesized may moderate medication through direct metabolism cognitive processes implicated hunger/satiety. Future should aim explore long-term safety, tolerability, efficacy profiles various treatment prevention abnormal metabolic homeostasis populations.

Language: Английский

Citations

2
Effect of Cariprazine on Anhedonia in Patients with Bipolar I Depression: Post Hoc Analysis of Three Randomized Placebo-Controlled Clinical Trials DOI Creative Commons
Roger S. McIntyre, Pierre‐Michel Llorca,

Lauren C. Aronin

et al.

Advances in Therapy, Journal Year: 2024, Volume and Issue: 42(1), P. 246 - 260

Published: Nov. 9, 2024

Anhedonic symptoms in bipolar I (BP-I) depression are associated with decreased quality of life and impaired functioning. We evaluated the effects cariprazine patients BP-I lower or higher levels anhedonia at baseline. Data were pooled from three clinical trials (NCT01396447, NCT02670538, NCT02670551) analyzing 1.5 3 mg/day adults depression. During post hoc analysis, stratified by baseline median Montgomery-Åsberg Depression Rating Scale (MADRS) factor score into a (score < median) ≥ subgroup. Outcomes included change to week 6 MADRS total score, latter also after adjusting for other depressive symptoms. Between-group differences compared using least-squares mean (LSMD) analyzed via mixed-effect model repeated measures. Median was 19, defining (placebo = 211; 200, 212) 249; 261, 250) subgroups. In subgroup, but not superior placebo reducing (LSMD [95% CI] − 2.61 [− 4.28, 0.93], P .0024) scores (− 1.70 2.77, 0.62], .0021) 6. both doses significantly greater reductions than (1.5 3.01 4.84, 1.19], .0012; 3.26 5.12, 1.40], .0006) 1.97 3.13, 0.81], .0009; 2.07 3.26, 0.89], .0006). Anti-anhedonic preserved symptoms, suggesting effect pseudospecific. Patients subgroup had therefore may have floor effect. Cariprazine demonstrated antidepressant specific anti-anhedonic regardless ClinicalTrials.gov identifiers, NCT02670551, NCT01396447. Anhedonia, lack interest pleasure, is common medication approved treatment However, its on unclear. To understand anhedonia, we combined data trials. mg per day) weeks against who before they started treatment. A 1383 study. There 623 760 anhedonia. more depressed overall those day better Our results suggest that reduces

Language: Английский

Citations

0